SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Add as a preferred source on Google
Illumina Inc. is selling its cancer test developer, Grail, following its series of antitrust conflicts. The company is a known maker of gene-sequencing machines, and on Sunday, Dec. 17, it revealed its decision to divest this unit, which it bought in 2021 for $7.1 billion.
According to The New York Times, Illumina's move to divest its Grail unit came two days after the company recently lost in a court battle. It made an appeal, but the federal court largely sided with the Federal Trade Commission when it upheld the antitrust regulator's ruling that Illumina must sell its Grail on antitrust grounds.
Obstruction in Europe
It was reported that Illumina's deal for Grail was also not cleared in Europe, and it has, in fact, faced a roadblock there, too. In September last year, the EU said it would block the acquisition. The company publicly admitted that it had been unsuccessful with its appeals for the Grail deal, and this has led to the decision to divest the start-up.
At any rate, the company's troubles started when it went ahead and purchased the cancer test developer despite the complaint from the U.S. FTC. The commission argued that the buyout would reduce innovation in the American market as well as increase prices.
Execution of Illumina's GRAIL's Sale
The biotechnology company, headquartered in San Diego, California, said that its sale of GRAIL is set to be executed via a third-party or capital markets transaction that is in line with the European Commission's (EU) divestiture order. Illumina aims to finalize the terms of the deal by the end of the second quarter of 2024.
"We are committed to an expeditious divestiture of GRAIL in a manner that allows its technology to continue benefitting patients," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "The management team and I continue to focus on our core business and supporting our customers. I am confident in Illumina's opportunities and our long-term success."
Photo by: Illumina Press Release
